Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Tribunal sided with ten generic makers of Crestor
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 27, 2014 12:54:34
Intellectual Property Tribunal sided with ten pharmaceutical companies, ruling that AstraZeneca’s patent on the composition of Crestor is invalid, sources said on December 26.

The patent with a stabilizing agent of Crestor was supposed to expire in August 2020. The ten companies include Ildong, Dream Pharma, Chong Kun Dang, Yuhan, Dong-A ST, Hanmi, Daewoong, Handok, SK Chemicals, and Jeil.

Korean pharmaceutical companies rolled out their generic version of Crestor in April, regardless of the pending patent case, concluding that patent was not solid enough to prevent them from putting their generic versions on the market. Two more patent cases of Crestor are still pending.

Crestor sales were 84.5 billion won last year. More than 50 generic versions were rolled out as soon as the patent on the substance of Crestor expired in April 2014.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com